Skip to main content
  • Efficacy and Safety of Riluzole in Acute Spinal Cord Injury (SCI). Rationale and Design of AOSpine Phase III Multi-center Double Blinded Randomized Controlled Trial. (RISCIS).

    Final Number:

    Michael G. Fehlings MD PhD FRCSC FACS; Branko Kopjar MD; Robert G. Grossman MD; Jefferson R. Wilson MD

    Study Design:
    Clinical Trial

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2014 Annual Meeting

    Introduction: There is convincing evidence from the preclinical realm that the pharmacologic agent riluzole attenuates certain aspects of the secondary injury cascade leading to diminished neurological tissue destruction in animal SCI models. The safety and pharmacokinetic profile of riluzole have been studied in a multicenter pilot study in 36 patients. Efficacy of riluzole in acute human SCI has not been established.

    Methods: This Phase II/III multi-center double-blind randomized controlled trial will involve up to 35 sites. A total of 351 patients with acute C4—C8 SCI and ASIA Impairment Grade A, B or C will be randomized 1:1 to riluzole and placebo. Primary outcome is the change in ASIA Total Motor Score between baseline and 180 days. Other measures include ASIA Upper Extremity Motor Score; ASIA Lower Extremity Motor Score; ASIA Sensory Score; ASIA grade; Spinal Cord Independence Measure); SF-36v2; EQ-5D and GRASSP. The statistical design utilizes 2-stage sequential adaptive trial. A sample size of 316 subjects (158 in each arm) will have 90% power to detect 9 points difference in the ASIA Motor Score at one-sided alpha = .025. To account for losses to follow-up of up to 10%, the study will enroll 351 subjects.

    Results: Within the Phase 1 study a matched cohort analysis was performed comparing complication rates and neurological outcomes between patients who received riluzole and matched non-riluzole treated patients from a prospective SCI registry. Although the groups experienced similar rates of complications, riluzole treated cervical SCI patients experienced an additional 15.5 points in AMS recovery at 90 days post injury as compared to non-riluzole treated patients. Although the phase I study was underpowered to investigate efficacy the current phase II/III study is poised to definitive address this question. Subject enrollment for this trial began October 1, 2013.

    Conclusions: This is a pivotal study of riluzole in acute SCI.

    Patient Care: This is a pivotal study of riluzole in acute SCI. To evaluate the efficacy and safety of riluzole in acute human SCI.

    Learning Objectives: To evaluate the efficacy and safety of riluzole in acute human SCI.


We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy